Domvanalimab Biosimilar - Research Grade

Human

TIGIT

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Human TIGIT (4E1.2) In Vivo Antibody - Low Endotoxin (ICH1219), Anti-Mouse TIGIT (1G9) In Vivo Antibody - Low Endotoxin (ICH1220), Tiragolumab Biosimilar - Research Grade (ICH5078), Vibostolimab Biosimilar - Research Grade (ICH5159), Tamgiblimab Biosimilar - Research Grade (ICH5279), Belrestotug Biosimilar - Research Grade (ICH5384), Dargistotug Biosimilar - Research Grade (ICH5465), Etigilimab Biosimilar - Research Grade (ICH5536), Lancastotug Biosimilar - Research Grade (ICH5623), Ociperlimab Biosimilar - Research Grade (ICH5722), Ralzapastotug Biosimilar - Research Grade (ICH5803), Renvistobart Biosimilar - Research Grade (ICH5816)

https://www.imgt.org/mAb-DB/

ICH3002

Q495A1

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of domvanalimab, a human IgG1-kappa antibody directed against TIGIT (T-cell immunoreceptor with Ig and ITIM domains; UniProt Q495A1). It is supplied strictly for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the same human TIGIT target as the originator, it is useful as a reference binder and tool reagent for characterising the TIGIT checkpoint axis in vitro and in preclinical settings. Typical research applications include use as a positive control or benchmarking standard in binding and blocking assays, epitope and competition studies, flow cytometry panels probing TIGIT-expressing lymphocytes, and as a comparator in ADCC or antibody-engineering workflows. The material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support assay development, screening campaigns, and reproducible lot-to-lot comparisons. It allows laboratories to interrogate TIGIT biology without sourcing clinical-grade therapeutic material. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on activated T cells, regulatory T cells, and natural killer (NK) cells. Its extracellular immunoglobulin domain binds the nectin-family ligands CD155 (PVR) and, with lower affinity, CD112 (nectin-2), competing with the co-stimulatory receptor CD226 (DNAM-1) for these ligands. Engagement of TIGIT delivers inhibitory signals through its cytoplasmic ITIM and ITT-like motifs, dampening T-cell and NK-cell activation, cytotoxicity, and cytokine production, while also reinforcing regulatory T-cell suppressive function. Because TIGIT restrains anti-tumour and antiviral immune responses and is frequently co-expressed with PD-1 on exhausted lymphocytes, it is a prominent immune-checkpoint target; blocking the TIGIT-CD155 interaction can shift the balance toward CD226-mediated co-stimulation and restored effector activity.

V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks